Intensity Therapeutics is a clinical-stage biotechnology company engaged in developing anti-cancer immune activation. Co.'s proprietary technology platform, DfuseRxSM involves the direct injection into tumors and diffuse therapeutic agents into cancer cells. Co.'s lead product candidate, INT230-6 consists of two anti-cancer cytotoxic agents, cisplatin and vinblastine sulfate, mixed in water with the amphiphilic molecule (SHAO) is used for sarcoma, breast and also lung cancer. The INTS average annual return since 2023 is shown above.
The Average Annual Return on the INTS average annual return since 2023 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether INTS average annual return since 2023 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the INTS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|